- Phase 3 HDV D-LIVR (Lonafarnib) Planned to Complete Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) Planned to Initiate in 2H21 - Zokinvy™ EMA Approval Expected in 2H21 - Strong Cash Position with ~$176M Pro Forma Cash to Begin 2021 PALO ALTO, Calif. , Jan.

- Eiger and The Progeria Research Foundation will share proceeds 50/50   - Non-dilutive capital further strengthens Eiger's balance sheet PALO ALTO, Calif. , Nov. 23, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted

- Zokinvy increases survival by 2.5 years in children and young adults with Progeria   - Rare Pediatric Disease Priority Review Voucher issued to Eiger from FDA   - Eiger to host an investor call, November 23, at 8:30 AM ET / 5:30 AM PT PALO ALTO, Calif. , Nov.